RxDoctor Payments Data

Shaileshkumar Desai, MD

Internal Medicine · Southfield, MINPI 1225046220

Payments from drug & device makers

$802in general payments, 2019–2025

Across 34 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$221
  • Medtronic$116
  • Merck$107
  • Pfizer$79
  • AstraZeneca$66
  • Lilly USA, LLC$54
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$72290%
  • Education$8010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson11$221
Medtronic1$116
Merck2$107
Pfizer4$79
AstraZeneca5$66
Lilly USA, LLC3$54
Otsuka America Pharmaceutical, Inc.2$41
Corcept Therapeutics1$35
Novo Nordisk1$28
Edwards Lifesciences1$23
Exact Sciences1$14
Vivaquant Inc, Dba Rhythm Express1$12
TMS Neurohealth Centers Inc.1$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$802 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$114,699
Medicare patients
251
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$44,819
JanuviaSitagliptin Phosphate11$17,001
JardianceEmpagliflozin11$15,917
OzempicSemaglutide11$9,989
Atorvastatin Calcium205$2,567
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,061
Levothyroxine Sodium146$1,944
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,583
Losartan Potassium95$1,337
Pantoprazole Sodium86$1,250
Metoprolol Succinate65$1,230
Rosuvastatin Calcium50$697
Potassium Chloride34$691
Amlodipine Besylate87$641
Metformin Hcl65$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$44,81941 claims
MerckJanuvia$107$17,00111 claims
Novo NordiskOzempic$28$9,98911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →